TY - JOUR
T1 - Medical cannabis
T2 - Another piece in the mosaic of autoimmunity?
AU - Katz, D.
AU - Katz, I.
AU - Porat-Katz, B. S.
AU - Shoenfeld, Y.
N1 - Publisher Copyright:
© 2016 American Society for Clinical Pharmacology and Therapeutics
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Legalization of cannabis' medicinal use is rapidly increasing worldwide, raising the need to evaluate medical implications of cannabis. Currently, evidence supports cannabis and its active ingredients as immune-modulating agents, affecting T-cells, B-cells, monocytes, and microglia cells, causing an overall reduction in pro-inflammatory cytokine expression and an increase in anti-inflammatory cytokines. Due to the supporting evidence of cannabinoids as an immune-modulating agent, research focusing on cannabinoids and autoimmunity has emerged. Several clinical trials in multiple sclerosis, inflammatory bowel disease, and fibromyalgia suggest cannabis' effectiveness as an immune-modulator. However, contradicting results and lack of large-scale clinical trials obscure these results. Although lacking clinical research, in vitro and in vivo experiments in rheumatoid arthritis, diabetes type 1, and systemic sclerosis demonstrate a correlation between disease activity and cannabinoids.
AB - Legalization of cannabis' medicinal use is rapidly increasing worldwide, raising the need to evaluate medical implications of cannabis. Currently, evidence supports cannabis and its active ingredients as immune-modulating agents, affecting T-cells, B-cells, monocytes, and microglia cells, causing an overall reduction in pro-inflammatory cytokine expression and an increase in anti-inflammatory cytokines. Due to the supporting evidence of cannabinoids as an immune-modulating agent, research focusing on cannabinoids and autoimmunity has emerged. Several clinical trials in multiple sclerosis, inflammatory bowel disease, and fibromyalgia suggest cannabis' effectiveness as an immune-modulator. However, contradicting results and lack of large-scale clinical trials obscure these results. Although lacking clinical research, in vitro and in vivo experiments in rheumatoid arthritis, diabetes type 1, and systemic sclerosis demonstrate a correlation between disease activity and cannabinoids.
UR - http://www.scopus.com/inward/record.url?scp=85007190465&partnerID=8YFLogxK
U2 - 10.1002/cpt.568
DO - 10.1002/cpt.568
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27859024
AN - SCOPUS:85007190465
SN - 0009-9236
VL - 101
SP - 230
EP - 238
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 2
ER -